ARTICLE | Clinical News
ETC-642: Began Phase I testing
October 15, 2001 7:00 AM UTC
Esperion Therapeutics Inc. (ESPR), Ann Arbor, Mich. Product: ETC-642 Business: Cardiovascular Therapeutic category: Metabolism Target: Cholesterol Description: Peptide and phospholipid mimic of apol...